Table 1 Patient characteristics, and exploration of prognostic factors associated with disease-free survival.

From: Efficacy and toxicity of post-neoadjuvant trastuzumab emtansine in HER2-positive breast cancer patients treated at Institut Curie Hospitals

Characteristic

Total

N = 102

According to relapse

No relapse

N = 95

Relapse

N = 7

p-value

Female, N (%)

102 (100%)

   

Age, median (interquartile range)

51 (42–60)

51 (44–61)

43 (39–50)

0.12

Tumor type, N (%)

   

0.2

Invasive carcinoma of no special type

99 (97%)

93 (98%)

6 (86%)

 

Invasive lobular carcinoma

2 (2%)

1 (1%)

1 (14%)

 

Invasive micropapillary carcinoma

1 (1%)

1 (1%)

0 (0%)

 

cTa, N (%)

   

0.4

1

10 (10%)

10 (11%)

0 (0%)

 

2

71 (70%)

67 (71%)

4 (57%)

 

3

18 (18%)

15 (16%)

3 (43%)

 

4

3 (3%)

3 (3%)

0 (0%)

 

cNa, N (%)

   

0.04

0

42 (41%)

42 (44%)

0 (0%)

 

1–3

60 (59%)

53 (56%)

7 (100%)

 

   N1

59 (58%)

52 (55%)

7 (100%)

 

   N2

0 (0%)

0 (0%)

0 (0%)

 

   N3

1 (1%)

1 (1%)

0 (0%)

 

RCB, N (%)

   

0.7

1

28 (27%)

27 (29%)

1 (14%)

 

2

62 (61%)

57 (61%)

5 (71%)

 

3

11 (11%)

10 (11%)

1 (14%)

 

Unknown

1 (1%)

1 (1%)

0 (0%)

 

ypT, N (%)

   

0.2

0

3 (3%)

3 (3%)

0 (0%)

 

1

81 (80%)

76 (81%)

5 (71%)

 

2

15 (15%)

14 (15%)

1 (14%)

 

3

2 (2%)

1 (1%)

1 (14%)

 

4

0 (0%)

0 (0%)

0 (0%)

 

Not applicable

1 (1%)

1 (1%)

0 (0%)

 

ypN, N (%)

   

0.1

0

62 (61%)

60 (63%)

2 (29%)

 

1–3

39 (38%)

34 (36%)

5 (71%)

 

   ypN1

31 (30%)

26 (27%)

5 (71%)

 

   ypN2

7 (7%)

7 (7%)

0 (0%)

 

   ypN3

1 (1%)

1 (1%)

0 (0%)

 

Not assessed

1 (1%)

1 (1%)

0 (0%)

 

Gradeb, N (%)

   

0.2

2

46 (45%)

41 (43%)

5 (71%)

 

3

56 (55%)

54 (57%)

2 (29%)

 

Hormone receptor status, N (%)

   

0.2

ER and/or PR positive

70 (69%)

67 (71%)

3 (43%)

 

ER and PR negative

32 (31%)

28 (29%)

4 (57%)

 

BMI, N (%)

   

0.6

<30, N (%)

86 (84%)

79 (83%)

7 (100%)

 

>30, N (%)

16 (16%)

16 (17%)

0 (0%)

 

Performance Status, N (%)

   

> 0.9

0

96 (94%)

89 (94%)

7 (100%)

 

1

5 (5%)

5 (5%)

0 (0%)

 

2

1 (1%)

1 (1%)

0 (0%)

 

Previous neoadjuvant treatment, N (%)

    

Anthracycline

95 (93%)

   

Taxane

102 (100%)

   

Trastuzumab

102 (100%)

   

Pertuzumab

1 (1%)

   

Breast surgery, N (%)

    

Lumpectomy

50 (49%)

   

Mastectomy

52 (51%)

   

Node surgery, N (%)

    

Sentinel lymph node biopsy

40 (39%)

   

Axillary lymph node clearance

62 (61%)

   

Concomitant radiation therapy, N (%)

99 (97%)

   

Concomitant endocrine therapy, N (%)

68 (67%)

   

LH-RH agonist + Tamoxifen

1 (1%)

   

Tamoxifen

31 (30%)

   

LH-RH agonist + Aromatase inhibitor

3 (3%)

   

Aromatase inhibitor

33 (32%)

   
  1. RCB residual cancer burder, ER estrogen receptor, PR progesterone receptor, BMI body mass index, LH-RH luteinizing hormone-releasing hormone.
  2. acT and cN are respectively clinical tumor and lymph node classification at diagnosis, prior to neoadjuvant chemotherapy.
  3. bGrade was assessed at diagnosis, prior to neoadjuvant chemotherapy.
Back to article page